Management of Castration-Resistant Prostate Cancer
Management of Castration-Resistant Prostate Cancer
Prostate cancer is the second most common cause of death in American men, and a great majority of those men die with CRPC. There are currently four new agents approved in the USA for use in CRPC: cabazitaxel, AA, sipuleucel-T and denosumab. While the current first line treatments are docetaxel and sipuleucel-T, ongoing and future clinical trials of these new agents, different docetaxel regimens, and emerging and experimental agents aimed at novel targets will lead to changes in the current treatment algorithm outlined in this review.
Conclusion
Prostate cancer is the second most common cause of death in American men, and a great majority of those men die with CRPC. There are currently four new agents approved in the USA for use in CRPC: cabazitaxel, AA, sipuleucel-T and denosumab. While the current first line treatments are docetaxel and sipuleucel-T, ongoing and future clinical trials of these new agents, different docetaxel regimens, and emerging and experimental agents aimed at novel targets will lead to changes in the current treatment algorithm outlined in this review.
Source...